{"brief_title": "A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.", "brief_summary": "This study will measure the effectiveness and any side effects of LY317615 in patients with Diffuse large B-cell lymphoma (a sub-type of Non-Hodgkins Lymphoma).", "condition": ["Non-Hodgkin's Lymphoma"], "intervention_type": ["Drug"], "intervention_name": ["LY317615"], "description": ["500 mg, oral, daily, up to six 28 day cycles"], "other_name": ["enzastaurin"], "criteria": "Inclusion Criteria: - A diagnosis of recurrent or refractory Diffuse B-cell Non-Hodgkin's lymphoma. - Adequate organ functions. - Able to swallow capsules. Exclusion Criteria: - More than 3 prior treatments for this disease. - Serious heart problems.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Lymphoma", "Lymphoma, Non-Hodgkin", "Lymphoma, B-Cell", "Lymphoma, Large B-Cell, Diffuse"], "id": "NCT00042666"}